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Background: The World Health Organization (WHO) classifies Guinea-Bissau as having severe vitamin A deficiency
(VAD). To date, no national survey has been conducted. We assessed vitamin A status among children in rural
Guinea-Bissau to assess status and identify risk factors for VAD.
Methods: In a vitamin A supplementation trial in rural Guinea-Bissau, children aged 6 months to 2 years who were
missing one or more vaccines were enrolled, vaccinated and randomized to vitamin A or placebo. Provided
consent, a dried blood spot (DBS) sample was obtained from a subgroup of participants prior to supplementation.
Vitamin A status and current infection was assessed by an ELISA measuring retinol-binding protein (RBP) and
C-reactive protein (CRP). VAD was defined as RBP concentrations equivalent to plasma retinol <0.7 μmol/L; infection
was defined as CRP >5 ml/L. In Poisson regression models providing prevalence ratios (PR), we investigated
putative risk factors for VAD including sex, age, child factors, maternal factors, season (rainy: June-November; dry:
December-May), geography, and use of health services.
Results: Based on DBS from 1102 children, the VAD prevalence was 65.7% (95% confidence interval 62.9-68.5),
11% higher than the WHO estimate of 54.7% (9.9-93.0). If children with infection were excluded, the prevalence was
60.2% (56.7-63.7). In the age group 9–11 months, there was no difference in prevalence of VAD among children
who had received previous vaccines in a timely fashion and those who had not. Controlled for infection and other
determinants of VAD, the prevalence of VAD was 1.64 (1.49-1.81) times higher in the rainy season compared to the
dry, and varied up to 2-fold between ethnic groups and regions. Compared with having an inactivated vaccine as
the most recent vaccine, having a live vaccine as the most recent vaccination was associated with lower prevalence
of VAD (PR=0.84 (0.74-0.96)).
Conclusions: The prevalence of VAD was high in rural Guinea-Bissau. VAD varied significantly with season, ethnicity,
region, and vaccination status.
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Vitamin A deficiency (VAD) is a public health problem
in many low-income countries. Worldwide, the preva-
lence of VAD is estimated to be 190 million in
preschool-age children [1] causing 1–2 million deaths
annually [2]. VAD is defined to be of public health im-
portance if the national prevalence reaches 15% [3] using
a serum or plasma retinol concentration < 0.7 μmol/L as
cut-off for VAD [1,4]. Many countries lack data on vita-
min A status. In Guinea-Bissau, no national vitamin A
status survey has been conducted. Lacking biochemical
vitamin A data, VAD estimates for preschool-age chil-
dren are based on a regression model including the
proxy variables: gross domestic product, under-5-mor-
tality, and population growth rate. Using this method,
Guinea-Bissau has been classified by the World Health
Organization (WHO) as having a severe public health
problem with an estimated 54.7% (9.9-93.0) of preschool-
age children suffering from VAD [1]. Despite estimates of
a high prevalence of VAD, little xerophthalmia has been
observed in Guinea-Bissau [5]. In the present study we
assessed the vitamin A status and investigated risk factors
for VAD among 6-23-month-old children due to be
vaccinated in rural Guinea-Bissau.
Methods
Study population
The Bandim Health Project (BHP) runs a Health and
Demographic Surveillance System (HDSS) covering 182
randomly selected clusters of 100 women and their chil-
dren below 5 years of age in the 9 rural health regions of
Guinea-Bissau (Figure 1). The clusters are visited every 6Figure 1 Map of regions in Guinea-Bissau. Villages included in the studmonths by a team of field assistants. At each visit all
women in the fertile age are interviewed to register new
pregnancies and their children are followed until they
reach 5 years of age. The following information is collected
the first time a child is registered: sex of the child, date of
birth, birth facility, maternal ethnicity, maternal education,
and maternal age. At all visits, information is collected on
breast feeding status, whether a bed net is used, and vac-
cination and vitamin A supplementation (VAS) history.
The WHO recommended vaccination schedule in
Guinea-Bissau is illustrated in Figure 2. The WHO policy
of providing VAS at vaccination contacts after 6 months
of age has not been implemented in Guinea-Bissau, but
VAS is distributed during national campaigns. The present
study was carried out within a randomized placebo-
controlled trial testing the effect of providing VAS at the
first vaccination contact after 6 months of age (trial regis-
tration: clinicaltrials.gov, number NCT00514891). The
trial enrolled children from August 2007 to November
2010. Within the clusters all mothers were invited to par-
ticipate in the trial if their child 1) was between 6 months
and 2 years of age, 2) missed at least one routine vaccin-
ation, and 3) had not received VAS within the previous
month (national VAS campaigns were conducted in July
2007, December 2007, July 2008, January 2009, July 2009,
January 2010, and May 2010). No xerophthalmia was
observed among the children.
At enrolment into the trial, after written informed
consent was obtained by the present parent or guardian,
the children were weighed and measured, and the
mother was interviewed about whether she had given
the child medicine and whether the child coughed,y marked as dots.
Figure 2 Vaccine schedule in Guinea-Bissau. Consisting of BCG
vaccine, oral polio vaccine (OPV), diphtheria-tetanus-pertussis (DTP),
and measles vaccine (MV). In September 2008 DTP was exchanged
for diphtheria-tetanus-pertussis-Hepatitis B-H. Influenzae (Pentavalent)
vaccine and yellow fever vaccine was introduced to be given
together with MV. wk: weeks, mo: months.
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enrolment.
We originally planned to collect blood samples from
600 children at enrolment, prior to randomization, to
describe baseline vitamin A status among the children
and study risk factors for VAD. The study was observa-
tional and no sample size calculations were made. In the
beginning of the trial all eligible children in a village
were included in the study. However, enrolment
proceeded faster than expected and to describe the full
seasonal and geographical variation we continued sam-
pling five children from each village until samples from
both the rainy (June-November) and the dry (December-
May) season had been obtained in all regions. Hence, a
total of 1254 samples were collected.
The study was in compliance with the Helsinki Declar-
ation and was approved by the Ministry of Health in
Guinea-Bissau. The Danish Central Ethical Committee
provided its consultative approval.
Handling and processing of blood samples
Dried blood spots (DBS) were prepared by letting finger
prick blood drip onto filter paper (903 Protein Saver
Card, Whatman International, UK). The papers were left
to dry in a horizontal position protected from sunlight.
After drying for a few hours, samples were bagged indi-
vidually together with desiccant (Silica gel, Merck, NJ,
USA) and left at ambient temperature for 1–14 days.
Using this procedure, retinol-binding protein (RBP)
levels remain stable for at least two weeks [6]. Upon ar-
rival in the capital, samples were frozen at −20°C until
analysis at the National Laboratory in Guinea-Bissau.
Before analysis, samples were inspected for the presence
of desiccant and dissociated plasma. Any plasma dissoci-
ation, seen as a yellow discoloration outside the DBS, or
lack of desiccant was noted.
RBP and C-Reactive Protein (CRP) were measured
using a previously developed sandwich enzyme-linked
immunosorbent assay (ELISA) [7]. In brief, wells in two
96-well plates (Maxisorb C-shape, Nunc) were coated
with polyclonal anti-human RBP antibody (A0040, Dako
Denmark), and polyclonal anti-human CRP antibodies
(Q0329, Dako, Denmark) respectively. DBS were elutedin buffer overnight and added to the wells after washing.
After incubation and another round of washing, a sec-
ond anti-human RBP (ICL, Dako, Denmark) and CRP
antibody (Abcam, Dako, Denmark) conjugated to horse-
radish peroxidase was added. After a third round of in-
cubation and washing, tetramethylbenzidine was added.
After development of sufficient color, the reaction was
stopped by adding sulphuric acid. Finally, the con-
centration was measured by spectrophotometry. All
concentrations were measured in duplicates. If the coef-
ficient of variation between two RBP measurements
differed by > 20%, a second duplicate measurement
was carried out. If the CRP value was ≥ 3 and ≤ 7
mg/L and the coefficient of variation between two CRP
measurements differed by > 20%, a second duplicate
measurement was carried out. If the CRP value was ≥ 7
or ≤ 3 mg/L and the coefficient of variation > 20%, du-
plicates differing more than 10% in optical density com-
pared to the highest measured point on the standard
curve were re-measured. A HPLC measured plasma
sample was added as a quality control to each plate.
If the quality control differed by more than 20% from
the concentration measured by HPLC, the entire plate
was re-measured.
Determining vitamin a status
The blood concentration of retinol is under homeostatic
control and remains stable over a large range of vitamin
A storage concentrations [8]. Retinol is bound to RBP in
the blood in a ≈1:1 complex but saturation tends to be
lower with low retinol concentrations [9-11].
We used the WHO definition of subclinical VAD,
which is a plasma retinol concentration of < 0.7 μmol/L.
Previous estimates found by paired measurements of
plasma retinol by HPLC and RBP by ELISA showed that
a cut-off of 0.83 μmol/L for RBP was equivalent to a
cut-off of 0.7 μmol/L for plasma retinol [9,12]. Infection
lowers plasma retinol concentrations and acute phase
proteins may be used to correct for overestimation of
VAD due to infection [13]. We defined infection as a
plasma concentration of CRP > 5 mg/L.
To estimate the cut-offs for VAD and infection using
DBS, a total of 85 paired plasma and DBS samples were
obtained and measured for RBP and CRP by ELISA. The
paired measurements were used to form receiver operat-
ing characteristic curves. The areas under the curves
were 0.75 and 0.90 for RBP and CRP respectively. The
Youden index [14] was used to find the DBS cut-off
value of 0.749 which corresponded to the highest
combined sensitivity and specificity with regard to iden-
tifying individuals with VAD defined as plasma RBP <
0.83. The same was done for CRP, identifying the DBS
cut-off which corresponded best, in terms of sensitivity
and specificity, to a plasma CRP > 5 mg/L.
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Global positioning system (GPS) coordinates were mea-
sured at hospitals, at vaccination facilities, and at the
center of the village. Coordinates were loaded into
ArcMap 9.3 (ESRI, Redlands, CA) and transformed into
a Universal Transverse Mercator geographic coordinate
system. An elevation of zero using the Shuttle Radar
Topography Mission Digital Elevation Model (U.S. Geo-
logical Survey, Reston, VA) was used to define the sea.
Euclidian distance in ArcMap was used to calculate the
distances between villages and nearest vaccination facil-
ity, hospital, and the sea, respectively.
Z-scores for anthropometry
Z-scores for weight-for-age, length-for-age, weight-for
-length, and arm circumference-for-age were calcula-
ted using the WHO health growth standards [15] and
the WHO Anthro version 3.1, June 2010 macro for
Stata [16].
Statistical analysis
First, we assessed the overall prevalence of VAD in all
enrolled children. To correct for an overestimation due
to infection, we subsequently conducted an analysis in
which we omitted all children with infection. Next, in a
sensitivity analysis, we assessed the prevalence of VAD
using a 10% lower or 10% higher cut-off (0.749 ±
0.0749) in order to test the importance of the cut-off for
VAD.
Since only children missing a vaccine according to the
vaccination schedule were included in the study, the
estimates of the prevalence of VAD may not entirely re-
flect vitamin A status in the population. The measles
vaccine is supposed to be given at 9 months of age but
children can be given this vaccine up to 12 months of
age without this being considered as a late vaccination.
We therefore defined a subgroup of children as being
”timely vaccinated” if they were 9–11 months of age,
had received the third dose of DTP/Pentavalent vaccine
before 7 months of age and were missing only MV
(Figure 2). Next, we studied the prevalence of VAD
within this subgroup and included it in our simple
model for risk factors for VAD (see below).
We examined the risk factors for VAD in Poisson re-
gression models, obtaining prevalence ratios (PR) for
VAD [17]. For all continuous variables, we investigated
whether there was evidence of a linear relationship be-
tween the variable and the prevalence of VAD by
inspecting the prevalence of VAD in quintiles of the
variable. If the association looked linear we tested for de-
parture from linearity by inclusion of a quadratic term.
Where evidence against linearity was not found, the
variable was included as a continuous variable; otherwise
the variable was included as categorical variables. Alinear relationship with VAD could not be shown for the
variables: length-for-age, distance to sea, distance to hos-
pital, and distance to vaccination place.
For z-scores, the normal score was used as reference
in the regression models. For distance variables, the
lowest distance was used as reference. For the remaining
variables the largest group was used as reference.
Variables included in the analysis of risk factors for VAD
are presented in Table 1. Variables were grouped under
six headlines: obligatory variables (age, sex, and infection
(CRP>5 mg/L)), child factors, season, geography, use of
health services, and maternal factors (Table 1).
All variables were tested one by one in a simple model,
controlling only for infection. In a larger model we
included the obligatory variables as well as all variables
from the simple model, and used automated stepwise
backwards selection to exclude variables to a descending
value of p<0.20. Wald tests were used to test for overall
equality of categories within variable. If a variable missed
information for less than 2% of the participants, the
missing category was excluded from both the simple and
the large model. This was the case for the variables:
weight for age, length for age, weight for length, breast
feeding, cough at the day of inclusion, fever at the day of
inclusion, diarrhea at the day of inclusion, maternal eth-
nicity, maternal educational level, maternal age, most re-
cent vaccination type, VAS within 6 months, and child
use of bed net (Additional file 1: Table S1).
To assess whether there was a temporal effect of previ-
ous VAS on vitamin A status we also tested the effect of
including children who had received VAS within 2, 4,
and 6 months prior to inclusion into the trial in the sim-
ple and the large model.
For all risk factors we evaluated whether the effect on
VAD varied by sex and by infection status, respectively,
by inclusion of an interaction term in both the simple
and the large model. All interactions were evaluated by
Wald statistics; a p-value below 0.05 was considered sig-
nificant. Unless otherwise stated only the results of the
large model are presented.
Finally we conducted a sensitivity analysis where we
tested if the conclusions regarding risk factors for VAD
changed if we a) excluded all children with infection, or
b) used the 10% lower or higher cut-off for VAD.
All statistical analyses were conducted using Stata/
SE 11.1.
Results
A total of 1254 samples were collected between August
2007 and November 2009. Of the 1254 samples, eight
samples were lost, two came from children who should
not have been included, two samples did not have a
corresponding inclusion questionnaire, 71 samples had
been stored without desiccant, and 69 had dissociated
Table 1 Risk factors for vitamin A deficiency in rural Guinea-Bissau













Yes 724 (66) - - - - -
No 378 (34) - - -
Obligatory
Sex
Male 555 (50) 67 reference 0.39 reference 0.09
Female 547 (50) 64 0.96 (0.89-1.05) 0.93 (0.86-1.01)
Age
Continuous (months) 1102 (100) - 0.99 (0.98-1.00) 0.05 1.00 (0.99-1.01) 0.83
CRP
≤ 5 mg/L 756 (69) 60 reference 0.0001 reference 0.0001
> 5 mg/L 346 (31) 78 1.29 (1.19-1.40) 1.27 (1.17-1.37)
Child factors
Weight for aged,e
Continuous 1094 (99) - 0.98 (0.95-1.02) 0.42 1.05 (0.99-1.11) 0.13
Arm circumference for aged,e
Continuous 1101 (100) - 0.95 (0.91-0.99) 0.02 0.95 (0.89-1.01) 0.09
Length for aged,e
< −2 267 (24) 62 1.01 (0.89-1.16) - -
≥ −2, < −1 325 (30) 67 0.93 (0.81-1.06) - -
≥ −1, < 0 345 (31) 67 0.99 (0.87-1.13) - -
≥ 0 161 (15) 50 reference 0.50 - -
Weight for lengthd,e
Continuous 1090 (99) - 0.99 (0.95-1.02) 0.49 - -
Twinning status
Singletons 1066 (97) 65 reference 0.001 reference 0.01
Twins 36 (3) 86 1.31 (1.15-1.49) 1.30 (1.11-1.52)
Breast feedingd
Yes 1080 (98) 66 reference 0.51 - -
Stopped 17 (2) 59 0.88 (0.61-1.27) -
Took medicine on inclusion day
No 975 (88) 65 reference 0.05f - -
Yes 63 (6) 71 1.03 (0.88-1.22) -
No information 64 (6) 77 1.19 (1.03-1.37) -
Cough at the day of inclusiond
No 816 (74) 64 reference 0.03 reference 0.03
Yes 283 (26) 72 1.11 (1.01-1.21) 1.10 (1.01-1.21)
Fever at the day of inclusiond
No 758 (69) 64 reference 0.42 - -
Yes 341 (31) 69 1.04 (0.95-1.13) -
Diarrhea at the day of inclusiond
No 920 (83) 65 reference 0.36 - -
Yes 178 (16) 69 1.05 (0.94-1.17) -
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Table 1 Risk factors for vitamin A deficiency in rural Guinea-Bissau (Continued)
Maternal factors
Maternal ethnicityd
Balanta 282 (26) 62 reference 0.0001 reference 0.001
Fula 215 (20) 81 1.31 (1.18-1.46) 1.21 (1.03-1.42)
Mandinga 123 (11) 61 0.98 (0.83-1.16) 0.88 (0.75-1.03)
Pepel 235 (21) 61 0.95 (0.83-1.08) 1.38 (1.05-1.81)
Otherg 234 (21) 62 1.00 (0.87-1.14) 0.95 (0.82-1.09)
Maternal educational level (years of school)d
None 797 (72) 66 reference 0.50 - -
1-4 197 (18) 61 0.93 (0.83-1.05) -
> 4 101 (9) 67 1.01 (0.87-1.16) -
Maternal age at child inclusion dated
≥ 14, ≤ 20 202 (18) 64 0.98 (0.87-1.10) -
> 20, ≤ 30 575 (52) 65 reference 0.74 - -
> 30, ≤ 40 260 (24) 68 1.04 (0.94-1.15) -
> 40, ≤ 55 43 (4) 61 0.96 (0.75-1.22) -
Season
Season
Dry 649 (59) 53 reference 0.0001 reference 0.0001
Rainy 453 (49) 84 1.56 (1.44-1.70) 1.64 (1.49-1.81)
Geography
Region
Bafata 121 (11) 55 1.02 (0.84-1.24) 1.41 (1.03-1.94)
Biombo 287 (26) 56 reference 0.0001 reference 0.0001
Bijagós/Bolama 63 (6) 76 1.41 (1.19-1.66) 2.46 (1.79-3.39)
Cacheu 53 (5) 43 0.81 (0.59-1.12) 1.47 (0.98-2.19)
Gabu 148 (13) 82 1.47 (1.30-1.67) 2.10 (1.53-2.87)
Oio 89 (8) 91 1.62 (1.44-1.83) 1.96 (1.49-2.58)
Quinara 133 (12) 68 1.22 (1.04-1.42) 1.98 (1.48-2.66)
Sao Domingos 91 (8) 65 1.15 (0.96-1.38) 1.87 (1.38-2.53)
Tombali 117 (11) 63 1.13 (0.96-1.33) 2.07 (1.51-2.83)
Village distance to vaccination facility (km)
≥ 0, < 0.5 440 (40) 69 reference 0.10 reference 0.19
≥ 0.5, < 2 167 (15) 60 0.88 (0.77-1.01) 1.09 (0.94-1.26)
≥ 2, < 5 200 (18) 61 0.88 (0.78-1.00) 1.07 (0.91-1.26)
≥ 5 295 (27) 67 0.98 (0.89-1.09) 1.17 (1.01-1.36)
Distance to sea (km)
≥ 0, < 5 25 9 (24) 63 reference 0.001 - -
≥ 5, < 15 290 (26) 60 0.96 (0.85-1.10) -
≥ 15, < 50 328 (30) 65 1.05 (0.93-1.19) -
≥ 50, < 149 225 (20) 77 1.22 (1.09-1.37) -
Distance to hospital (km)
≥ 0, < 10 206 (19) 65 reference 0.03 reference 0.04
≥ 10, < 20 363 (33) 72 1.09 (0.97-1.22) 1.06 (0.93-1.20)
≥ 20, < 30 319 (29) 61 0.94 (0.82-1.07) 0.93 (0.81-1.07)
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Table 1 Risk factors for vitamin A deficiency in rural Guinea-Bissau (Continued)
≥ 30, < 70 214 (19) 63 0.96 (0.83-1.11) 0.86 (0.72-1.02)
Use of health services
Most recent vaccination typed,h
Inactivated 667 (61) 67 reference 0.93 reference 0.06
Live 141 (13) 64 0.96 (0.84-1.09) 0.84 (0.74-0.96)
Mixed 156 (14) 66 1.00 (0.88-1.13) 1.01 (0.90-1.13)
No vaccination 119 (11) 47 0.99 (0.86-1.14) 1.01 (0.88-1.17)
VAS received within 6 monthsd
Received 589 (53) 63 reference 0.12 - -
Not received 500 (45) 68 1.07 (0.98-1.17) -
Birth facility
Home 629 (57) 65 reference 0.01 reference 0.02
Health unit/center 80 (7) 58 0.89 (0.73-1.08) 0.98 (0.82-1.17)
Hospital 126 (11) 77 1.20 (1.07-1.34) 1.16 (1.03-1.31)
No information 267 (24) 64 1.00 (0.90-1.11) 1.13 (1.03-1.25)
Child use of bed netd
Year around 773 (70) 67 reference 0.03 reference 0.03
Rainy season 311 (28) 63 0.94 (0.85-1.04) 0.97 (0.87-1.09)
None 8 (1) 88 1.38 (1.06-1.80) 1.48 (1.11-1.97)
aPoisson regression adjusted for CRP > 5 mg/L, bPoisson regression adjusted for CRP > 5 mg/L, sex, age, weight for age, arm circumference for age, twinning
status, cough on inclusion day, maternal major ethnic group, season, region, village distance to vaccination facility, distance to hospital, most recent vaccination
type, birth facility, and child use of bed net. cWald test for overall equality of categories within variable. dNumbers do not add up to 1102 because records with
missing information were discarded if they represent < 2%, ez-score in standard deviations from 1. fp=0.68 when children missing information was omitted,
gGrouped from minor ethnicities. hVaccination status determined by the most recent vaccination type being either live (BCG, OPV, MV, and/or yellow fever
vaccine), inactivated (DTP or Pentavalent vaccine) or Mixed (both a live and an inactivated vaccine). OPV is supposed to be given with DTP vaccines, but the last
vaccine type was not considered as mixed if OPV was given with a DTP or Pentavalent vaccine as done in previous studies.
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Due to missing information on a variable (Additional file
1: Table S1) the final number of children included in the
large model was 1050.Overall prevalence of VAD and infection
The overall prevalence of VAD was 65.7% (95% CI=62.9-
68.5). The prevalence of infection was 31.4% (28.7-34.4).
If we excluded all children with infection, the prevalence
of VAD was 60.2% (56.7-63.7). Using a 10% lower cut-off
it was 57.5% (54.6-60.5) and using a 10% higher cut-off
it was 73.5% (70.9-76.1).Risk factors for VAD
Sex of the child had no significant effect on the preva-
lence of VAD but girls tended to have slightly lower
prevalence of VAD, the PR for VAD being 0.93 (0.86-
1.01) (Table 1). The risk of VAD tended to decrease with
increasing age in the simple model. However, the mar-
ginal effect disappeared after adjustment (Table 1). As
expected, having an infection was associated with an
increased risk of VAD, the PR being 1.27 (1.17-1.37).Child factors
Arm circumference was associated with VAD in the sim-
ple model, but not in the large model after adjustment
(Table 1). None of the other anthropometric variables
were associated with VAD. Twins had a higher risk of
VAD (the PR being 1.30 (1.11-1.52)), while breastfeeding
had no effect on VAD. Cough on the inclusion day was
positively associated with VAD (PR=1.10 (1.01-1.21)),
whereas fever and diarrhea and use of medicine on the
date of enrolment were not (Table 1).Maternal factors
Fula and Pepel ethnicity were associated with an
increased prevalence of VAD compared with Balanta
ethnicity (PR=1.21 (1.03-1.42) and 1.38 (1.05-1.81), re-
spectively) (Table 1). Maternal educational level and age
were not associated with VAD.Season
Rainy season (June to November) was associated with a
high risk of VAD, the PR being 1.64 (1.49-1.81)
compared with the dry season (December-May). The
lowest risk of VAD was found at the end of the dry
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VAD was 46.5% (42.3-50.8) (Figure 3).
Geography
There were considerable differences in the prevalence of
VAD between the nine health regions (Figure 1 and
Table 1). The regions of Bijagós/Bolama, Gabu, and
Tombali had a more than 2-fold higher prevalence of
VAD compared to the region of Biombo which is clos-
est to the capital (the PRs being 2.46 (1.79-3.39), 2.10
(1.53-2.87), 2.07 (1.51-2.83) respectively). A distance
equal to or above 5 km to a vaccination facility did
not increase the risk of VAD in the simple model but
were associated with a higher risk in the large model
(PR=1.17 (1.01-1.36)). Although distance to the sea
was associated with a higher prevalence of VAD in the
simple model (Table 1), no linear relationship with
VAD was found, and due to confounding by region
the variable was not included in the large model. Dis-
tance to hospital was associated with VAD, but in a
non-linear manner (Table 1).
Use of health services
Having received a live vaccine as the most recent vac-
cine rather than an inactivated vaccine was associated
with a lower risk of VAD (PR= 0.84 (0.74-0.96) (Table 1)).
We did not find an effect on the risk of VAD of having
received VAS within the previous 6 months (Table 1).
VAS within 2 or 4 was not associated with significantly
lower risk of VAD either (Additional file 1: Table S2).
Hospital delivery was associated with an increased risk
of VAD (PR=1.16 (1.03-1.31)) compared to home deliv-
ery. The eight children who did not use bed net at any
time of the year had a higher risk of VAD than children
who used bed nets all year (PR=1.48 (1.11-1.97)).
A total of 380 children were 9–11 months of age.
Of these, 124 children were timely vaccinated. TheFigure 3 Prevalence of VAD by month in Guinea-Bissau.
Number of samples tested indicated in the lower part of each bar.prevalence of VAD was 61% in the group of timely
vaccinated children and 69% in those who had not been
timely vaccinated. The risk of VAD was not significantly
different between the two groups (PR=0.92 (0.76-1.10) in
the timely vaccinated versus the non-timely vaccinated
(Additional file 1: Table S3).
Interactions between risk factors and sex and infection
We found no interactions between sex and any of the
risk factors retained in the large model. There were sig-
nificant interactions between infection and weight for
age (p<0.0001), ethnicity (p<0.001), season (p<0.01), and
region (p<0.001), respectively; in children with infection
the associations between these risk factors and VAD
were less pronounced.
Sensitivity analysis
If children with infection were excluded, retaining 756
children in the analysis, cough on inclusion became in-
significant in both models, arm-circumference-for-age
was no longer significantly associated with VAD in the
simple model, and most recent vaccination type became
statistically significant in the large model (Additional file
1: Table S4).
Using the low cut-off for VAD thereby retaining only
the most deficient children by setting the cut-off for VAD
lower than 0.83, identified the same main risk factors for
VAD in the large model with a few exceptions. Twinning
status was no longer a risk factor and birth facility, and
distance to hospital was no longer risk factors in any of
the models (Additional file 1: Table S5).
Using a high cut-off for VAD also identified the same
main risk factors in the large model except for birth fa-
cility that was no longer significant in the large model,
and the use of bed net that was no longer significant in
the both models (Additional file 1: Table S6).
Discussion
Main findings
Based on the collected blood samples young children in
rural Guinea-Bissau may have a major VAD problem.
The overall prevalence of VAD was 66%, 11% higher
than the WHO estimate. Infection, twinning, cough on
inclusion day, Fula and Pepel ethnicity, rainy season, liv-
ing in the regions of Bijagós/Bolama, Gabu, and
Tombali, and hospital delivery were associated with an
increased risk of VAD. Receiving a live vaccine as the
most recent vaccine was associated with a lower preva-
lence of VAD compared with having received an
inactivated vaccine as the most recent vaccine. These
factors remained significant or became even more
pronounced when children with infection were excluded
(Additional file 1: Table S5).
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No national vitamin A status study has been conducted
in Guinea-Bissau and the present study is the first to de-
scribe the determinants of VAD. Using a DBS assay ap-
proach allowed for the collection of samples from many
areas within the country, which would not have been
possible if we had used plasma or serum samples due to
lack of electricity.
A limitation that may possibly contribute to an overesti-
mation of VAD in the study is the incomplete correction
for infection by not including α1-acid-glycoprotein, and/
or another slow acute phase protein in the models [13].
In the present study we took advantage of the infra-
structure of a trial and only children eligible for the trial
were bled. Thus, children were between 6–23 months of
age and missed at least one routine vaccination, and no
children were included in the first month after VAS
provided in a campaign. Children with incomplete vac-
cination history have been shown to have a higher risk
of VAD in other settings [18]. However, in our study
population in rural Guinea-Bissau it is common to be
missing one or more vaccines; in a recent study from
the Bandim Health Project we found that half of the
children at one year of age in Guinea-Bissau are missing
at least one vaccine [19]. Furthermore, 67% of children
in the age group from 9–11 months of age had not yet
received a measles vaccine at the time of the home visit,
and we did not find any statistical difference in the risk
of VAD between the children who had received all the
prior vaccines timely and children who had not. Hence,
though we cannot exclude a slight overestimation of
VAD due to the focus on children missing one or more
vaccines, we believe that the study reflects the situation
in rural Guinea-Bissau.
Since study children did not receive VAS within the
preceding month, a short-lived increase in serum RBP
after supplementation in a campaign is not likely to have
affected the results [20]. On the other hand, we might
have overestimated the prevalence of VAD by not in-
cluding this group. However, we were not able to docu-
ment any effect of receiving VAS from 1 to 2 months
before inclusion.
All geographic areas were represented in the sample.
However, the included populations did not completely
correspond to the respective population sizes in the vari-
ous regions. Due to the inter-regional variation in risk of
VAD this could have affected the overall estimate of
VAD prevalence. However, calculating a weighted aver-
age the combined prevalence from all regions was 67%.
The four months with the lowest prevalence of VAD
corresponded to 48.2% of the study population, which
will tend to underestimate the prevalence of VAD.
In conclusion, we may not have obtained a precise es-
timate of the true prevalence of VAD in the children inGuinea-Bissau, but neither setting the cut-off for VAD
lower, nor exclusion of infected children or estimating
the prevalence of VAS in timely vaccinated children
resulted in a prevalence below 57.5% as estimated by the
WHO. The analysis of determinants of VAD was also
robust in the sensitivity analyses.
Consistency with other studies
Several studies of vitamin A status in children have
investigated determinants for VAD. Since the Bandim
Health Project have previously observed sex differences
in the effect of vitamin A supplementation [5,21-23] sex
was included as an obligatory variable in the analysis.
However, most studies have found no sex differences of
VAD [9,24,25] and our study is in line with this, though
with a tendency towards lower VAD in girls.
In countries where VAD is a public health problem,
the WHO recommends VAS every 4–6 months [26].
Several trials have evaluated the temporal effect of sup-
plementation on VAD, but none including children
within the study age group. We found only two studies
investigating the effect of VAS on vitamin A status in
the present age group. An observational study from
Ethiopia reported increased VAD in children who had
missed one or more doses of VAS within the last year
[18]. The other observational study collected paired
blood samples before and after supplementation and
found a significant increase in plasma retinol 4 months
after VAS [27]. We could not document any effect of
missing VAS within the preceding 2, 4 or 6 months. Pos-
sible explanations could be geographical or methodo-
logical differences between the studies. The study from
Ethiopia also reported an effect on VAD of missing a
vaccine and coming from a Muslim household. We did
not find a consistent effect of coming from a Muslim
household. The Fulas are Muslims and had a high preva-
lence of VAD, but so are the Mandingas, who did not
have a high prevalence of VAD.
Seasonal differences in vitamin A status have been
documented in West Africa before, both in children [28]
and in lactating and pregnant mothers [29,30]. Our results
also show strong seasonal differences, and these were par-
ticularly pronounced in children without infection.
We have previously shown that the inactivated DTP
vaccine given after neonatal VAS was associated with
reduced RBP levels in 4 months old girls [9]. In the
present study the prevalence of VAD was higher if the
most recent vaccine was DTP compared with a live vac-
cine (MV, BCG, OPV), but the effect did not differ by
sex in these older children.
Interpretation
The important dietary sources of pre-formed vitamin A
are animal products such as egg and liver. In addition,
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vegetables and fruits such as mango as well as in red
palm oil [31-33] can be converted to retinoids [34]. All
of the above foods can be found in Guinea-Bissau. We
found strong seasonal variation in the prevalence of
VAD and a possible explanation could be food availabil-
ity. Mango supply might partly explain seasonal va-
riation in vitamin A status, either directly or through
breastfeeding [29,35] although the mango season starts a
month later than the months with a low prevalence of
VAD. The decreased prevalence of VAD in the dry sea-
son could also be explained by the harvest in December-
January. Underestimation of infection may also partly
explain why season is a strong predictor but this seems
unlikely since no significant difference in the prevalence
of a high CRP between seasons was found (30% (27–34)
and 33% (29–37) in the dry and rainy season, respect-
ively). It seems likely that vitamin A status follows the
intake of vitamin A rich foods and to a lesser degree
VAS since season was a strong predictor for VAD, but
VAS within the preceding months was not. If the WHO
guidelines were to be followed, special attention should
be given to improving vitamin A status in risk situations,
e.g. in the rainy season. However, several studies from
Guinea-Bissau have shown that supplementing with vita-
min A in the rainy season may have a negative impact
on overall mortality [20,36]. This emphasizes that VAS
may have other effects than merely prevention of VAD.
The reason for the strong regional differences is not
clear. Distance to the sea was confounded by region and
might explain the high risk of VAD in the region of
Gabu. We have no explanation why hospital deliveries
were associated with a higher risk of VAD; this might be
a spurious finding.
The increased risk of VAD amongst twins could pos-
sibly be explained by a lower nutritional status since
twins are more often born low-birth-weight and run a
higher risk of being stunted [37]. However, due to the
low number of twins (n=36) the result should be
interpreted with caution.
The lower prevalence of VAD among children who
had a live vaccine as their most recent vaccine supports
previous observations that live vaccines are associated
with beneficial effect on child health [38,39].
Conclusion
We found that around two-thirds of children between 6
months and 2 years of age have RBP levels indicating
VAD. Though we only included children who were not
fully vaccinated, this accounts for a large proportion of
the children in rural Guinea-Bissau, and there was no in-
dication that children vaccinated timely had significantly
lower risk of VAD. Though we may not have been able
to control fully for the effect of infections, the resultsstill point to VAD as a major public health problem in
rural Guinea-Bissau. In our analysis of determinants we
found that major risk factors were season, region, ethni-
city, and vaccination status. The prevalence of VAS var-
ied up to 2-fold between different groups, hence it is
possible to identify subgroups of children at particular
risk. In light of the missing effects of VAS on vitamin A
status it may be better to opt for other methods to im-
prove vitamin A status, i.e. through fortification, pro-
moting vitamin A rich foods or more frequent low-dose
supplementation.
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